Palvella (PVLA) director awarded 6,000 stock options vesting over 3 years

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Palvella Therapeutics director Matthew Pauls received a grant of stock options representing rights to buy 6,000 shares of common stock. The options have an exercise price of 154.84 per share and expire on June 29, 2036. They vest in 36 equal monthly installments, conditioned on his continued service, and his derivative holdings after this grant total 6,000 options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pauls Matthew

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 6,000 options Exercise price: 154.84 per share Expiration date: June 29, 2036 +2 more

5 metrics

Options granted 6,000 options Stock Option (Right to Buy) grant to director Matthew Pauls

Exercise price 154.84 per share Exercise price of granted stock options

Expiration date June 29, 2036 Expiration of the granted stock options

Vesting schedule 36 monthly installments Vesting conditioned on continued service

Derivative holdings after grant 6,000 options Total options held following the transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "154.8400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:06 PM Accepted by SEC EDGAR 07/01/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauls Matthew

(Last)

(First)

(Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$154.84	06/29/2026		A		6,000		⁽¹⁾	06/29/2036	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Palvella Therapeutics (PVLA) report for Matthew Pauls?

Palvella Therapeutics reported that director Matthew Pauls received a grant of stock options for 6,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of shares.

How many Palvella Therapeutics (PVLA) stock options were granted to Matthew Pauls?

Matthew Pauls was granted stock options covering 6,000 shares of Palvella Therapeutics common stock. These options are a derivative security giving him the right to buy shares if he meets the vesting and exercise conditions.

What is the exercise price and expiration date of Matthew Pauls’ PVLA stock options?

The granted stock options have an exercise price of 154.84 per share and expire on June 29, 2036. Pauls must exercise the options before that expiration date to acquire the underlying common shares.

How do Matthew Pauls’ Palvella Therapeutics (PVLA) options vest over time?

The options vest in 36 equal monthly installments, subject to Matthew Pauls’ continued service on each vesting date. This means a portion becomes exercisable each month over three years as long as he remains in service.

Is Matthew Pauls’ Form 4 transaction in PVLA an open-market buy or sell?

The Form 4 shows a grant of stock options, categorized as a grant, award, or other acquisition. It is not an open-market buy or sell; it represents compensation that may later be exercised into common shares.

How many Palvella Therapeutics (PVLA) options does Matthew Pauls hold after this grant?

Following the reported grant, Matthew Pauls holds 6,000 stock options directly. These options relate to Palvella Therapeutics common stock and become exercisable over time according to the 36-month vesting schedule.